These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Are we living in the end of the blockbuster drug era? Debnath B; Al-Mawsawi LQ; Neamati N Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653 [TBL] [Abstract][Full Text] [Related]
3. Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs. Ablavsky G; Larrimore Ouellette L JAMA Intern Med; 2018 Feb; 178(2):179-180. PubMed ID: 29297039 [No Abstract] [Full Text] [Related]
4. Vertical integration: the drug industry and prescription benefits managers. Gibaldi M Pharmacotherapy; 1995; 15(3):265-71. PubMed ID: 7667161 [No Abstract] [Full Text] [Related]
5. Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value. Huskamp HA Health Aff (Millwood); 2006; 25(3):635-46. PubMed ID: 16684726 [TBL] [Abstract][Full Text] [Related]
6. Indian generics companies go on spending spree. Jayaraman KS Nat Rev Drug Discov; 2005 Aug; 4(8):616-7. PubMed ID: 16106583 [No Abstract] [Full Text] [Related]
7. Using a drug-safety tool to prevent competition. Sarpatwari A; Avorn J; Kesselheim AS N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666 [No Abstract] [Full Text] [Related]
8. Skies darken over drug companies. Holmes D Lancet; 2012 May; 379(9829):1863-4. PubMed ID: 22616103 [No Abstract] [Full Text] [Related]
9. [Discount for only one drug of the same group leads to impaired health care quality]. Bergström R Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044 [No Abstract] [Full Text] [Related]
10. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers. Rea TS Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713 [No Abstract] [Full Text] [Related]
11. Patent cliff mitigation strategies: giving new life to blockbusters. Kakkar AK Expert Opin Ther Pat; 2015; 25(12):1353-9. PubMed ID: 26372691 [TBL] [Abstract][Full Text] [Related]
12. The ongoing regulation of generic drugs. Frank RG N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956 [No Abstract] [Full Text] [Related]
13. The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry? Sarpatwari A; Kesselheim AS PLoS Med; 2016 Feb; 13(2):e1001955. PubMed ID: 26859662 [TBL] [Abstract][Full Text] [Related]
14. Pricing increases for cancer drugs sparks investigation. Venkatesan P Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213 [No Abstract] [Full Text] [Related]
15. Handle with care. Macilwain C Nature; 2006 Apr; 440(7087):990-1. PubMed ID: 16625170 [No Abstract] [Full Text] [Related]
16. Drugs: budget busters or cost cutters in future health care? Egger E Health Care Strateg Manage; 1999 Mar; 17(3):1, 22-3. PubMed ID: 10351640 [No Abstract] [Full Text] [Related]
17. Who Needs XR, LA, SR, XL, ER, or CR? Curtiss FR J Manag Care Pharm; 2005; 11(9):772-3, 775-6. PubMed ID: 16300421 [No Abstract] [Full Text] [Related]